Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296424 · ClinicalTrials.gov registry record · Phase 3
ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 182
- Enrollment target
NCT02296424 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 182 participants.
The verdict
NCT02296424, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 182 participants
- Enrollment target
Study Summary
The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
Interventions
- DRUG ACZ885 150 mg (Canakinumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2014-11-17 |
| Est. Completion | 2017-09-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02296424
The ClinicalTrials.gov registry entry for NCT02296424 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACZ885 150 mg (Canakinumab) is the first listed.
NCT02296424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02296424 about?
NCT02296424 is a clinical study titled "ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab". The purpose of this study was to evaluate the efficacy observed with canakinumab dose reduction in a subgroup of patients in the extension study CACZ885G2301E1.
What is the current status of trial NCT02296424?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 182 participants. The study started on 2014-11-17. Estimated completion is 2017-09-25.
What interventions are being tested in trial NCT02296424?
The interventions under investigation include: ACZ885 150 mg (Canakinumab) (DRUG).
Who is sponsoring clinical trial NCT02296424?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.